



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Bae Abertawe
Swansea Bay University
Health Board

Cadeirydd Dros Dro/ Interim Chair: **Emma Woollett**
Prif Weithredwr/Chief Executive: **Tracy Myhill**

gofalu am ein gilydd, cydweithio, gwella bob amser
caring for each other, working together, always improving

Rydym yn croesawu gohebiaeth yn y Gymraeg ac yn y Saesneg. We welcome correspondence in Welsh or English.

Dyddiad/Date: 4th December 2019
Ein Cyf / Our Ref: 19-K-008

☎ 01639 648363

✉ FOIA.Requests@wales.nhs.uk

[REDACTED]

Corporate Services
Headquarters
1 Talbot Gateway
Baglan
Port Talbot, SA12 7BR

[REDACTED]

I refer to your Freedom of Information Act Request acknowledged by ourselves on 7th November 2019. Your request sought information relating to homecare services.

1. **In your organisation, which named individuals have the overall responsibility for any homecare provision for your patients?**

Judith Vincent, Clinical Director of Pharmacy.

2. **Do you currently have in post an operational lead for homecare services in your organisation – If so, what is their name/role?**

Reuben Morgan, Medicines Homecare Manager

3. **What are your organisations minimum requirements for accepting a homecare provider?**

They would need to be affiliated to the National Clinical Homecare Association, and returned on the All Wales Low and Mid Tech tender.

4. **If you have an outsourced outpatient pharmacy, are they able to provide nurse services / training for patients on how to self-inject for medicines administered by sub-cutaneous injection as part of their contract?**

Not applicable.

Can you please advise of total numbers of NHS patients who;



Pencadlys BIP Bae Abertawe, Un Porthfa Talbot, Port Talbot, SA12 7BR / Swansea Bay UHB Headquarters, One Talbot Gateway, Port Talbot, SA12 7BR

Bwrdd Iechyd Prifysgol Bae Abertawe yw enw gweithredu Bwrdd Iechyd Lleol Prifysgol Bae Abertawe
Swansea Bay University Health Board is the operational name of Swansea Bay University Local Health Board

5. Can you please advise of total numbers of NHS patients; who received a homecare delivery service of drug and/or nurse service at dates Jan 2018 / Jan 2019 / October 2019 – please provide these numbers by;

a. Drug name

b. Therapy / clinical area

Please see information below in response to question (a) and (b) - drug name and clinical area.

Drug name	Therapy / Clinical Area	Number of patients		
		Jan 18	Jan 19	Oct 19
Advate (Factor VIII)	Haematology	<5	<5	<5
Afinitor (Everolimus)	Cancer	10	13	20
Aimovig (Erenumab)	Neurology	0	0	16
Alprolix (Factor IX)	Haematology	<5	<5	<5
Amgevita (Adalimumab)	Gastroenterology	0	<5	71
Amgevita (Adalimumab)	Dermatology	0	<5	92
Aubagio (Teriflunomide)	Neurology	<5	<5	<5
Avonex (Interferon beta-1a)	Neurology	9	9	11
Baraclude (Entecavir)	Hepatology	0	0	<5
Benepali (Etanercept)	Rheumatology	285	292	406
Benepali (Etanercept)	Dermatology	15	18	21
Betaferon (Interferon beta-1b)	Neurology	<5	<5	<5
Bosulif (Bosutinib)	Cancer	<5	<5	<5
Braftovi (Encorafenib) & Mektovi (Binimetinib)	Cancer	0	0	<5
Bramitob (Tobramycin)	Cystic Fibrosis	<5	<5	<5
Cabometyx (Cabozantinib)	Cancer	<5	<5	9
Cimzia (Certolizumab Pegol)	Rheumatology	25	35	45
Cimzia (Certolizumab Pegol)	Gastroenterology	0	<5	<5
Copaxone (Glatiramer Acetate)	Neurology	56	59	63
Cosentyx (Secukinumab)	Rheumatology	39	70	101
Cosentyx (Secukinumab)	Dermatology	40	49	51
Crysvita (Burosumab)	Endocrinology	0	0	<5
Duodopa (Co-Careldopa)	Neurology	5	6	6
Dupilixent (Dupilumab)	Dermatology	0	18	37
Enbrel (Etanercept)	Rheumatology	311	333	345
Enbrel (Etanercept)	Dermatology	8	8	9
Epclusa (Sofosbuvir/Velpatasvir)	Hepatology	76	101	146
Erbitux (Cetuximab)	Cancer	<5	<5	<5
Esbriet (Pirfenidone)	Respiratory	11	29	45
Fampyra (Fampridine)	Neurology	16	16	16
Forsteo (Teriparatide)	Rheumatology	33	42	49
Forsteo (Teriparatide)	Endocrinology	<5	<5	<5
Genotropin (Somatropin)	Endocrinology	0	0	<5
Gilenya (Fingolimod)	Neurology	35	36	37
Glivec (Imatinib)	Cancer	0	7	10



Harvoni (Ledipasvir/Sofosbuvir)	Hepatology	79	133	147
Hemlibra (Emicizumab)	Haematology	0	0	<5
Herceptin (Trastuzumab)	Cancer	218	227	251
Humira (Adalimumab)	Rheumatology	544	549	590
Humira (Adalimumab)	Gastroenterology	189	195	212
Humira (Adalimumab)	Dermatology	115	118	124
Humira (Adalimumab)	Ophthalmology	<5	<5	<5
Ibrance (Palbociclib)	Cancer	0	29	43
Ilumetri (Tildrakizumab)	Dermatology	0	0	<5
Imbruvica (Ibrutinib)	Cancer	0	<5	5
Imnovid (Pomalidomide)	Cancer	0	0	10
Imraldi (Adalimumab)	Rheumatology	0	162	448
Imraldi (Adalimumab)	Gastroenterology	0	<5	12
Imraldi (Adalimumab)	Dermatology	0	0	16
Inlyta (Axitinib)	Cancer	17	19	21
Jakavi (Ruxolitinib)	Cancer	<5	5	7
Kevzara (Sarilumab)	Rheumatology	0	<5	<5
Keytruda (Pembrolizumab)	Cancer	0	16	23
Kineret (Anakinra)	Rheumatology	6	6	6
Kisqali (Ribociclib)	Cancer	0	<5	<5
Kyntheum (Brodalumab)	Dermatology	6	19	23
Mavenclad (Cladribine)	Neurology	5	10	13
Maviret (Glecaprevir / Pibrentasvir)	Hepatology	56	113	170
Mekinist (Trametinib)	Cancer	<5	<5	<5
Norditropin (Somatropin)	Endocrinology	<5	7	8
Ocaliva (Obeticholic Acid)	Hepatology	0	<5	7
Ofev (Nintedanib)	Respiratory	29	43	57
Olumiant (Baricitinib)	Rheumatology	30	132	217
Omnitrope (Somatropin)	Endocrinology	<5	<5	<5
Opdivo (Nivolumab)	Cancer	<5	12	16
Orencia (Abatacept)	Rheumatology	137	161	176
Otezla (Apremilast)	Rheumatology	0	0	31
Plegridy (Peginterferon beta-1a)	Neurology	36	38	44
Rebif (Interferon beta-1a)	Neurology	24	25	25
ReFacto AF (Factor VIII)	Haematology	5	6	7
Repatha (Evolocumab)	Endocrinology	0	14	17
Revlimid (Lenalidomide)	Cancer	0	<5	13
Risperdal Consta (Risperidone)	Mental Health	147	163	170
RoActemra (Tocilizumab)	Rheumatology	105	137	167
Sandostatin Lar (Octreotide)	Cancer	<5	<5	<5
Simponi (Golimumab)	Rheumatology	69	73	76
Simponi (Golimumab)	Gastroenterology	<5	5	5
Skyrizi (Risankizumab)	Dermatology	0	0	<5
Soliris (Eculizumab)	Haematology	<5	<5	<5
Soliris (Eculizumab)	Nephrology	<5	<5	<5
Somatuline Autogel (Lanreotide)	Cancer	55	59	64



Somatuline Autogel (Lanreotide)	Endocrinology	<5	<5	<5
Somavert (Pegvisomant)	Endocrinology	0	0	<5
Sovaldi (Sofosbuvir)	Hepatology	38	38	38
Sprycel (Dasatinib)	Cancer	<5	5	5
Stelara (Ustekinumab)	Rheumatology	11	14	19
Stelara (Ustekinumab)	Gastroenterology	8	21	32
Stelara (Ustekinumab)	Dermatology	107	118	123
Stivarga (Regorafenib)	Cancer	<5	<5	<5
Sutent (Sunitinib)	Cancer	24	28	30
Tafinlar (Dabrafenib)	Cancer	31	45	65
Taltz (Ixezumab)	Rheumatology	0	0	<5
Taltz (Ixezumab)	Dermatology	15	17	19
Tasigna (Nilotinib)	Cancer	7	11	12
Tecentriq (Atezolizumab)	Cancer	0	<5	<5
Tecfidera (Dimethyl Fumarate)	Neurology	88	101	107
Tivozanib (Fotivda)	Cancer	<5	11	20
Tremfya (Guselkumab)	Dermatology	0	16	31
Trevicta (Paliperidone)	Mental Health	0	0	<5
Trientine dihydrochloride	Hepatology	<5	<5	<5
Velcade (Bortezomib)	Cancer	<5	<5	<5
Venclyxto (Venetoclax)	Cancer	0	<5	<5
Verzenio (Abemaciclib)	Cancer	0	0	<5
Viekirax (Ombitasvir/Paritaprevir/Ritonavir)	Hepatology	99	99	99
Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)	Hepatology	0	<5	<5
Votrient (Pazopanib)	Cancer	76	102	119
Xeljanz (Tofacitinib Citrate)	Rheumatology	0	14	61
Xeplion (Paliperidone)	Mental Health	61	69	86
Xtandi (Enzalutamide)	Cancer	109	122	141
Zaponex (Clozapine)	Mental Health	6	6	6
Zejula (Niraparib)	Cancer	0	10	19
Zelboraf (Vemurafenib)	Cancer	<5	<5	<5
Zepatier (Elbasvir/Grazoprevir)	Hepatology	40	40	40
Zomacton (Somatropin)	Endocrinology	<5	<5	<5
Zydelig (Idelalisib)	Cancer	0	<5	<5
Zytiga (Abiraterone Acetate)	Cancer	50	53	81
Abacavir/Lamivudine	Sexual Health	N/A	N/A	37
Atripla (Tenofovir/Efavirenz/Emtricitabine)	Sexual Health	N/A	N/A	27
Biktarvy (Emtricitabine / Tenofovir Alafenamide)	Sexual Health	N/A	N/A	63
Darunavir	Sexual Health	N/A	N/A	6
Descovy (Emtricitabine/Tenofovir)	Sexual Health	N/A	N/A	41
Edurant (Rilpivirine)	Sexual Health	N/A	N/A	29
Efavirenz	Sexual Health	N/A	N/A	23
Efavirenz/Emtricitabine/Tenofovir	Sexual Health	N/A	N/A	66
Emtricitabine / Tenofovir Disproxil	Sexual Health	N/A	N/A	78
Emtriva (Emtricitabine)	Sexual Health	N/A	N/A	7
Eviplera (Emtricitabine/Tenofovir/Rilpivirine)	Sexual Health	N/A	N/A	14



Genvoya (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir)	Sexual Health	N/A	N/A	76
Intelence (Etravirine)	Sexual Health	N/A	N/A	6
Isentress (Raltegravir)	Sexual Health	N/A	N/A	33
Juluca (Dolutegravir / Rilpivirine)	Sexual Health	N/A	N/A	6
Kaletra (Lopinavir/Ritonavir)	Sexual Health	N/A	N/A	<5
Kivexa (Abacavir/Lamivudine)	Sexual Health	N/A	N/A	6
Lamivudine	Sexual Health	N/A	N/A	8
Nevirapine	Sexual Health	N/A	N/A	42
Norvir (Ritonavir)	Sexual Health	N/A	N/A	54
Odefsey (Emtricitabine/Rilpivirine/Tenofovir)	Sexual Health	N/A	N/A	5
Prezista (Darunavir)	Sexual Health	N/A	N/A	43
Reyataz (Atazanavir)	Sexual Health	N/A	N/A	<5
Rezolsta (Darunavir/Cobicistat)	Sexual Health	N/A	N/A	30
Stribild (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir)	Sexual Health	N/A	N/A	<5
Symtuza (Darunavir/Cobicistat/Emtricitabine/Tenofovir)	Sexual Health	N/A	N/A	15
Tivicay (Dolutegravir)	Sexual Health	N/A	N/A	53
Triumeq (Abacavir/Lamivudine/Dolutegravir)	Sexual Health	N/A	N/A	129
Truvada (Tenofovir/Emtricitabine)	Sexual Health	N/A	N/A	34
Viramune (Nevirapine)	Sexual Health	N/A	N/A	7
Viread (Tenofovir)	Sexual Health	N/A	N/A	6
Ziagen (Abacavir)	Sexual Health	N/A	N/A	12
Baraclude (Entecavir)	Sexual Health	N/A	N/A	<5

Please note that where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

c. By drug the name of the homecare provider who provided/provides this service

The information in relation to (c) is withheld under Section 43 Commercial Interests of the FOIA.

Section 43 of the Act sets out an exemption for the right to know if release of the information is likely to prejudice the commercial interests of any person (a person may be an individual, a company, the public authority itself or any other legal entity). Section 43 is a qualified exemption. That is, it is subject to the public interest test.

The homecare services market is a highly competitive rapidly expanding market with Pharma funded homecare services i.e. where one or more homecare providers are commissioned by a manufacturer of a drug (pharma company) and also NHS funded homecare schemes.



Section 43 guidance states:

'a commercial interest relates to a person's ability to participate competitively in a commercial activity. The underlying aim may be to make a profit however it could also be simply to remain solvent.

The risks are high should a manufacturer and product supplier cease trading with a homecare provider. This immediately impacts on the treatment and care of the patients. The choice of homecare provider becomes limited and the NHS is then forced to source alternative homecare arrangements.

The Health Board acknowledges that there is a public interest in transparency and in the accountability of with whom we spend our money. A large percentage of the homecare market is with the pharmaceutical companies who in turn commission homecare providers. In releasing this information, this in turn could lead to an unfair advantage to the suppliers competitors (this data along with the patient numbers associated with this particular homecare provider), along with impacting the treatment and care of our patients.

Therefore the Health Board considers that the public interest in withholding the information is greater than the interests in disclosing it and thereby giving unfair commercial advantage to competitors of the supplier to which this information concerns. The Health Board believes that disclosure of information in a manner which fails to protect the interests and relationships arising in a commercial context could have the effect of discouraging companies from dealing with the Health Board because of fears that the disclosure of information could damage them commercially. In turn this could then jeopardise the Health Board's ability to compete fairly and pursue its function to bring forward development in the area and obtain value for money. It was therefore decided that it was not in the public's interest to disclose this information.

d. If possible please identify if these services are NHS funded or pharmaceutical / manufacturer funded services.

The Health Board can confirm that the homecare services are a split between pharmaceutical funded and NHS funded, around 70/30 split, however as per above (c) we are unable to break this down due to Section 43 – Commercial Interests.

I hope this information is helpful. If you require anything further please contact us at FOIA.Requests@wales.nhs.uk.

Under the terms of the Health Board's Freedom of Information policy, individuals seeking access to recorded information held by the Health Board are entitled to request internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request please contact me directly at the address below or register your complaint via FOIA.Requests@wales.nhs.uk.

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 029 2067 8400.



Yours sincerely

P. a. wenger

Pam Wenger
Director of Corporate Governance

